Adverse Event Disclosure Standards Could Be Altered By Supreme Court In Matrixx Case

Supreme Court justices appeared skeptical of Matrixx Initiatives’ insistence that companies need not tell investors about reports of drug adverse events unless they are statistically significant, suggesting the court may set a different disclosure standard for a securities fraud suit.